

RETRACTED ARTICLE: *Panax notoginseng* Saponins Improve Angiogenesis in Coronary Heart Disease Based on the microRNA 200a Methylation Pathway

Jie Wang, Yan Dong, Zhaoling Li, Yun Zhang , Lanchun Liu, Guang Yang, Yongmei Liu, Jun Li, Lian Duan

Department of Cardiology, Guang Anmen Hospital, Beijing, People's Republic of China

Correspondence: Lian Duan, Email popale2003@163.com

Background: Improving angiogenesis in the ischemic myocardium is a therapeutic strategy for preventing, reducing, and repairing myocardial injury of coronary artery disease (CAD). *Panax notoginseng* saponins (PNS) have been widely used in the clinical treatment of cardiovascular diseases, demonstrating excellent efficacy, and can potentially improve angiogenesis in the ischemic myocardium. However, the effects of PNS on angiogenesis and its underlying mechanism of action remain unclear.

Purpose: In this study, we aimed to evaluate the role of PNS in improving angiogenesis after myocardial infarction (MI) and explain the mechanism of PNS in improving angiogenesis in CAD from an epigenetic perspective.

Study Design: The MI rat model was established by ligating the left anterior descending coronary artery permanently. The in vitro model comprised hypoxic human coronary artery endothelial cells (HCEACs). The mice and cells were then treated with PNS.

Methods: Blood tests, histomorphology, polymerase chain reaction, enzyme-linked immunosorbent assay, Western blotting, and MassARRAY targeted methylation detection analyses were conducted in vivo and in vitro to investigate the potential mechanisms of PNS.

Results: Oral PNS significantly improved myocardial injury and activated angiogenesis in MI rats. DNA methylation analysis in vitro revealed that PNS decreased the hypermethylation of microRNA 200a (miR200a). PNS improved angiogenesis in hypoxic human coronary artery endothelial cells (HCEACs) by regulating the vascular endothelial growth factor (VEGF) pathway.

Conclusion: Our research shows that PNS can improve angiogenesis in rats with MI and hypoxic HCEACs and affect the level of miR200a promoter methylation, miR200a and VEGF molecular pathways.

Keywords: *Panax notoginseng* saponins, coronary artery disease, DNA methylation, miRN200a, angiogenesis

Introduction

Coronary artery disease (CAD) is a serious condition that causes myocardial ischemia and hypoxia, leading to cell death. Currently, the primary treatments for CAD include drug therapy, interventional therapy, and coronary artery bypass grafting. However, after percutaneous coronary intervention the incidence of restenosis within 1 year after the intervention is as high as 33%, and the restenosis rate is even higher after 1 year.¹ There is a lack of effective treatment methods for patients with diffuse lesions at the distal end of the coronary artery, those with multivessel lesions that cannot tolerate surgery, and those in whom traditional treatment methods are poorly efficacious.² Therefore, improving angiogenesis in the ischemic myocardium, a therapeutic strategy for preventing, reducing, and repairing myocardial injury, remains highly anticipated.

Panax notoginseng saponins (PNS) are the active ingredients of *Panax notoginseng*. Oral and infusion preparations of PNS have been widely used to treat cardiovascular and cerebrovascular diseases in clinic and have demonstrated excellent efficacy.³ Notably, many studies have shown that PNS has anti-inflammatory, anti-platelet, and anti-atherosclerotic effects. Our previous randomized controlled trial (RCT) showed that PNS have good clinical efficacy in regulating lipids, stabilizing plaques, and exerting anti-inflammatory effects, which can improve angina symptoms.⁴

Long-term PNS treatment can reduce the endpoint of CAD effectively.⁵ The study also showed that PNS can affect microRNA (miRNA) expression and methylation.⁶

However, the effects of PNS on angiogenesis and its underlying mechanism of action remain unclear. Therefore, this study aimed to evaluate the role of PNS in improving angiogenesis after myocardial infarction (MI) and explain the mechanism of PNS in improving angiogenesis in CAD from an epigenetic perspective.

Methods

HPLC Fingerprint of PNS

The preparation of the reference solution was as follows: ginsenoside R1 (no. 110745–201,921), ginsenoside Rg1 (no. 110703–2,020,034), ginsenoside Re (no. 110754–202,129,) ginsenoside Rb1 (no. 110704–202,230) and ginsenoside Rd (no. 111818–202,104), at 20 mg each, from the National Institutes for Food and Drug Control were each placed in a 10-mL volumetric flask and dissolved as reference stock solutions. Notoginsenoside R1 and ginsenoside Rg1, Re, Rb1, and Rd were accurately measured in reserve solutions of PNS with volumes of 0.4, 1.6, 0.2, 2, and 1 mL, respectively, and placed in the same 10-mL volumetric flasks. They were then dissolved as mixed reference solutions (refer to the supplementary materials for detailed steps).

Animals

The maintenance of all animals is provided as guidelines for the US National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication 80–23, 1985). The animal studies were reviewed and approved by the institutional ethics committee of Guang Anmen Hospital. Wistar male rats were purchased from Charles River Company (Beijing, China). MI was induced through permanent ligation of the left anterior descending coronary artery in mice. 100 Clean-grade healthy Wistar male rats were fasted for 12 h before surgery, anesthetized intraperitoneally with 10% chloral hydrate, fixed, skinned, and disinfected. Tracheal intubation was performed through the mouth, the ventilator was connected, assisted breathing was performed, and a preoperative lead II electrocardiogram was recorded. The rat's chest was opened, and the anterior descending branch of the coronary artery in the 3rd to 4th intercostal space of the left chest was ligated. Only the same part of the rat's heart without ligation was threaded in the sham-operated group. The success criterion for the model was that the color of the myocardium below the ligation should turn grayish white, and the ST segment of the electrocardiogram should gradually elevate or become arched upwards (at least 2 mm higher than normal). The exclusion criteria for the model were preoperative findings of heart rate <350 bpm or arrhythmia in rats that had not recovered, no significant changes in myocardial color after ligation, no elevation of ST segment, and deaths before the time for sampling. Three days postoperatively, each rat was subcutaneously injected with a unit of penicillin to prevent infection.

Medication was administered 1 week postoperatively, and rats with MI were fed by gavage once a day for 28 days. Surviving rats were randomly divided into control (sham surgery); model; and high-, medium-, and low-dose PNS (2.44, 1.22, 0.61 g·kg⁻¹·d⁻¹, respectively) groups. According to the drug instructions, the normal dosage is 100mg orally three times a day. The dosage of the medium-dose PNS group was a 70 kg body weight adult equivalent dose (calculated based on body surface area). The medium dose is 1.22 g·kg⁻¹·d⁻¹ for mice. The high-dose group received twice the adult equivalent dose, and the low-dose group received half the adult equivalent dose. A 5% sodium carboxymethyl cellulose aqueous solution was used for gavage, as in the sham surgery and model groups with 10 mL·kg⁻¹. Two hours after postoperative recovery, the medication was administered with normal water and feed. Rats with successful acute MI models were fed once daily through oral gavage for 28 days.

Routine Blood and Biochemical Tests

After execution, the abdominal aorta blood sampling method was performed using rat-specific kits for routine blood and biochemical tests (reagents in [Table S2](#)).

Hematoxylin and Eosin Staining

Regarding myocardial tissue morphology, changes in myocardial cell morphology were observed using the hematoxylin and eosin (H&E) staining method.

Immunofluorescence staining to determine microvascular density was performed as follows: After cardiac perfusion, samples were collected and fixed in each rat group, and continuous frozen sections were obtained (30 μm). A mouse anti-rat CD31 polyclonal antibody (Recombinant Anti-CD31 antibody, Abcam) (1:40) was added dropwise, and the sample was incubated at 4 °C for 16 h. It was then incubated with a secondary antibody at 26 °C, and light Horcheste staining with 10 $\mu\text{g}\cdot\text{mL}^{-1}$ was avoided. The sample was finally sealed with an anti-fluorescence attenuation agent. CD31 is a specific marker of vascular endothelial cells and is commonly used to measure microvascular density. Microvessel density and wrapping of microvessels by astrocytes were observed under an immunofluorescence microscope, and quantitative analysis was performed using ImageJ software. Firstly, we observed the entire section under a low-power microscope (40x), select the n areas with the highest vascular density, and then count each of these n areas under a high-power microscope (200x).

miR200a Methylation Detection Scheme

Target gene sequences were queried (Table S3). Primer design was performed using Agena EpiDesigner software (<https://epidesigner.com/>) to determine the final fragment to be tested and the corresponding DNA site information. The corresponding PCR primer sequences for the fragments were synthesized using the PAGE primer purification method. DNA quality inspection included agarose gel electrophoresis and Nano OD detection. A NaHSO_3 reagent kit (Zymo Research, America) was used to process the DNA samples. PCR amplification was then performed. The PCR products were treated with shrimp alkaline phosphatase to remove free dNTPs from the system. Transcriptase cleavage was then performed to purify the resin. The Agena NanosuspenserRS1000 sampling instrument was used to transfer the purified resin product to the 384-well SpectroCHIP® On bioarray. Data were analyzed and output using EpiTYPER™.

5'-end primer sequence: aggaagagag TTTTTT TTTGGTTTTCAGTAT

3'-end primer sequence: cagtaatacgaactactatagggaaggga TATAAAAAACA CCCTAACCT CC

Quantitative RT-PCR

Detect miR200a, VEGF, Akt, and STAT3 mRNA. Quantitative RT-PCR. Refer to the supplementary materials for detailed steps.

Western Blotting

Detection of VEGF, Akt, and STAT3 via Western blotting. Refer to the supplementary materials for detailed steps.

Cell Culture

Endothelial cells were cultured using a hypoxic HCAEC model. Transfection of cells with an miR200a inhibitor resulted in the downregulation of microRNA expression. Using the direct administration method, the above mimetics and inhibitors were transfected into endothelial cells, mixed with H_2O_2 (0.1 $\mu\text{mol/L}$), and divided into control, model, PNS, and inhibitor transfection groups. After 24 h of administration, endothelial cells from each group were collected for scratch and microvessel formation assays (Refer to the supplementary materials for detailed steps). The regulatory relationship between miR200a and VEGF signaling pathways in the intervention of total saponins of *Panax notoginseng* in CAD was verified by analyzing target gene-related signaling pathways using qRT-PCR and Western blotting.

Results

Qualitative Analysis of Bioactive Components of PNS Tablets

The representative chemical components of PNS are Notoginsenoside R1, Ginsenoside Rg1, Ginsenoside Re, Ginsenoside Rd, and Ginsenoside Rb1 (Figure 1A–E). The main active ingredients of PNS tablets were determined using high-performance liquid chromatography (HPLC). The chromatograms of the main identified components of the




Figure 1 Chromatograph fingerprints of PNS analyzed using HPLC. **(A-E)**: The chemical structure of the main active ingredients of PNS, including Notoginsenoside R1, Ginsenoside Rg1, Ginsenoside Re, Ginsenoside Rd, and Ginsenoside Rb1; **(F)**: the injection spectra of the reference substance; **(G)**: the injection chromatogram of a representative sample of PNS tablet. 1, 2, 3, 4, and 5 represent notoginsenoside R1, ginsenoside Rg 1, ginsenoside Re, ginsenoside Rb 1, and ginsenoside Rd, respectively.

Table 1 Content of Panax Notoginseng Saponin Tablets

Content%	Batch 1:2110065	Batch 2:2111021	Batch 3:2111043
Notoginsenoside R1	7.38%	7.89%	7.19%
Ginsenoside Rg1	28.66%	28.49%	25.74%
Ginsenoside Re	4.23%	4.11%	3.51%
Ginsenoside Rb1	35.05%	37.64%	34.28%
Ginsenoside Rd	18.22%	19.13%	16.18%
Total saponin content	93.54%	97.27%	87.91%

PNS tablets are shown in [Figure 1F](#) and [G](#). Three batches of PNS tablets were tested for the main specified components, as presented in [Table 1](#). The pharmacopeia stipulates that each tablet should contain at least 8.0% of ginsenoside R1, at least 25.0% of ginsenoside Rg1, at least 2.5% of ginsenoside Re, at least 27.0% of ginsenoside Rb1, and at least 5.0% of ginsenoside Rd, and that the total amount of ginsenoside R1, ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, and ginsenoside Rd should be at least 75%. All three batches complied with these regulations.

PNS Effects on MI Rats

MI was induced through permanent ligation of the left anterior descending coronary artery in mice. Cardiac echocardiography showed abnormal ventricular wall motion in rats with MI. In a previous study, PNS improved CAD symptoms. High-density lipoprotein levels and white blood cell counts showed significant changes in the PNS group in a RCT.⁵ We tested the heart index in the present study and found no significant differences. Routine blood and coagulation function tests showed increased red blood cell count in rats with MI. Therefore, it was suggested that PNS can reduce red blood cell count. In cases where fibrinogen levels were significantly increased in MI rats ([Figure S1D](#)), PNS significantly reduced fibrinogen levels, indicating that PNS affected coagulation function. PNS had no abnormal effects on liver or kidney function ([Figure S1E–I](#)).

Angiogenesis Histological Changes Associated with PNS

Histological analysis revealed a significant reduction in MI-induced inflammation and injury ([Figure 2A](#) and [B](#)). Histological results showed that many amorphous lipids, irregular cholesterol crystal spaces, and foam cells were present at the ligation sites in the model group. Furthermore, many necrotic cells were observed at the edges. Fewer foam and inflammatory cells were observed in the low-, medium-, and high-dose PNS groups than in the model group. The aspirin group also showed amorphous lipids, irregular cholesterol crystal pores, and foam cells; however, these were fewer than those in the model group, with mild fibrosis.

We first investigated whether angiogenesis changes occurred in the hearts of mice with MI treated with PNS. In immunohistochemistry, CD31, primarily used to demonstrate the presence of endothelial cell tissue, is a marker of vascular endothelial cells and is a key factor involved in platelet adhesion and aggregation. It negatively regulates thrombosis by inhibiting platelet aggregation.⁷ We performed immunostaining of the CD31 protein and determined the average optical density of CD31⁺ cells in infarcted hearts treated with PNS. After MI, the staining level of CD31⁺ decreased, and the average optical density was significantly reduced. After treatment with low, medium, and high doses of PNS and aspirin, the staining intensity of CD31⁺ increased. The average optical density significantly increased, indicating that the number of new blood vessels in the myocardial tissue significantly increased after treatment with low, medium, and high doses of PNS and aspirin ([Figure 2C–E](#)).

PNS Action on Angiogenic Molecules

We confirmed that the expression level of CD31 protein in the myocardium of rats with MI was decreased in the model group. However, it was increased in low- and medium-dose PNS groups. This confirmed the reduction in endothelial cells in rats with MI, and PNS intervention restored the number of endothelial cells. We found significant changes in the expression levels of p-stat3 and p-AKT, which are important genes in the vascular endothelial growth factor (VEGF)




Figure 2 Histological changes associated with Panax notoginseng saponin in mice. **(A)**: H&E staining of myocardial infarction area ($\times 4$); **(B)**: H&E staining of myocardial infarction area ($\times 40$); **(C-E)**: Immunohistochemistry was performed on heart tissues to detect the expression of CD31+ on the surface of cardiac microvessels. Mean optical density (MOD): Compared with the control group, $***P < 0.001$. Compared with the model group, $^{\#}P < 0.05$, $^{\#\#}P < 0.01$, and $^{\#\#\#}P < 0.001$. The data is expressed as mean \pm SD, with a sample size of $n = 14$.




Figure 3 Panax notoginseng saponin (PNS) regulates CD31 (A) and activates important genes in the vascular endothelial growth factor (VEGF) signaling pathway. Western blot analysis of the myocardium revealed key proteins associated with the VEGF pathway, such as p38-MAPK (B), p-stat3 (C), p-AKT (D), and VEGF (E and F). Western blot of key enzymes of the VEGF pathway. C compared with the control group, * $P < 0.05$, *** $P < 0.001$. Compared with the model group, # $P < 0.05$, #### $P < 0.001$. The sample size is as following (CD31 $n = 6$; p38-MAPK $n = 8$; p-stat3, p-AKT, VEGF $n = 5$).

signaling pathway (Figure 2). Under normal physiological conditions, blood vessels in the body maintain high stability but are regulated by several key growth factors. VEGF is the most critical factor involved in mitosis and specifically acts on endothelial cells. It is produced and secreted by many cells and has a strong angiogenic effect.

PNS Promotes Angiogenesis and Inhibits Apoptosis in Human Coronary Artery Endothelial Cells

First, when using PNS with concentrations ranging from 1.56 $\mu\text{g/mL}$ to 800 $\mu\text{g/mL}$ to treat human coronary artery endothelial cells (HCEACs), we found that when the concentration exceeded 25 $\mu\text{g/mL}$, the cell inhibition rate gradually increased with increasing concentration (Figure 4A). Therefore, for conservatism, we set PNS concentrations in the subsequent administration to 0.39–50 $\mu\text{g/mL}$. The experimental results showed that oxygen-glucose deprivation/reperfusion (OGD/R) treatment significantly inhibited HCEAC proliferation. After treating HCEACs with PNS concentrations ranging from 0.39 $\mu\text{g/mL}$ to 50 $\mu\text{g/mL}$, we found that treatment with 1.56 $\mu\text{g/mL}$ PNS significantly improved cell proliferation. However, treatment with lower or higher concentrations of PNS had no significant effect (Figure 4B). Finally, the experiment confirmed that the optimal concentration of PNS was 1.56 $\mu\text{g/mL}$ for HCEACs with OGD/R-induced hypoxia.




Figure 4 Effects of Panax ginseng saponin (PNS) on the cell inhibitory rate of HCEACs. **(A)**: HCEACs were cultured with different PNS concentrations (0–800 µg/mL). The cell inhibitory rate was assessed using the Cell Counting Kit-8 (CCK8) assay after 12 h. **(B)**: In cases of hypoxia, HCEACs were cultured with different PNS concentrations (0.39–50 µg/mL) using the CCK8 assay after 12 h. **(C)**: Angiogenesis capacity of cells was observed using vessel formation assay ($\times 100$). **(D and E)**: Apoptosis was determined using TUNEL assay. A sample size is $n=7$. Control group: HCEACs in normal culture; Model group: 1% O_2 hypoxia culture; PNS group: 1.56 µg/mL concentration of PNS acts on hypoxic HCEACs; Inhibitor group: A hypoxia model was established 24 h after transfection with miR200a inhibitor; Compared with the control group, $***P<0.001$. Compared with the model group, $####P<0.001$.

The effect of ischemia on angiogenesis in HCEACs was determined through angiogenesis experiments, and the results showed that the angiogenic ability of the model group was inhibited compared with that of the control group. PNS affected the effect of ischemia on angiogenesis in HCEACs (Figure 4C). The terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay was used to compare the apoptotic cells, and it was found that the

percentage of apoptotic cells in the model group increased significantly compared with that in the control group. Furthermore, the proportion of apoptotic cells in the PNS group was significantly lower than that in the model group (Figure 4D and E).

miR200a and Its Pathways

Epigenetics is important in the development of CAD. Our previous study showed a DNA methylation-miRNA-mRNA network in CAD, with a different expression of miR200a. Using the MassARRAY DNA methylation quantitative detection method, we tested 24 sites, including 12 effective sites. The test results are shown in Figure 5. The heat map results showed significant differences among the control, model, and PNS groups. The methylation levels of the different groups at each site are shown in the bar chart in Figure 5. In model group, the level of mean DNA methylation decreased compared to the control group. Meanwhile, PNS could increase the level of mean DNA methylation compared to the model group with significant difference. After conducting homogenization statistics on the degree of methylation in each group, we found that the model group showed an upward trend in the degree of miR200a methylation; however, after PNS intervention, the degree of miR200a methylation decreased, with no significant difference observed (Figure 5A–D).

The angiogenic ability of HCEACs was inhibited in the model group. After treatment with the miR200a inhibitor, angiogenesis in HCEACs was slightly recovered compared with that in the model group. The TUNEL experiment was used to compare the apoptotic cells in each group, and the percentage of apoptotic cells in the model group increased significantly. Furthermore, the proportion of apoptotic cells was significantly lower in the inhibitor group than in the model group (Figure 4C–E).

Using a real-time quantitative PCR detection system (qPCR) to detect the expression of miR200a, we found significant differences in the expression level among the groups. The expression level in the model group was significantly higher than that in the control group. However, the PNS and inhibitor groups showed a significantly decreased expression level than the model group. The inhibitor group showed a significantly reduced expression level compared with the control group, indicating that the inhibitor group was more successful in modeling (Figure 5E).

Using an enzyme-linked immunosorbent assay (ELISA) to detect the protein expression level of VEGF and endothelin (ET)-1, we found that VEGF expression levels significantly increased under hypoxic conditions. Furthermore, blood vessels were extensively damaged under hypoxic conditions, and VEGF has a compensatory and significant increase. PNS and inhibitor groups showed a significant decrease in VEGF levels (Figure 5F). ET is not only present in the endothelium of blood vessels but is also widely present in various tissues and cells. It is essential in regulating cardiovascular function and maintaining basal vascular tension and cardiovascular system homeostasis. Under hypoxic conditions, the ET-1 levels significantly increased. Furthermore, blood vessels were extensively damaged under hypoxic conditions. The PNS and inhibitor groups showed relatively stable cell states, indicating a significant decrease in ET-1 levels compared with the model group (Figure 5G).

After analyzing the western blotting results of the key proteins, endothelial nitric oxide synthase (eNOS), AKT, and STAT3, and their phosphorylation status in the VEGF signaling pathway, we found no significant changes in the protein expression levels of eNOS, AKT, and STAT3. However, hypoxia models and PNS and inhibitor interventions significantly altered the phosphorylation status of the three key proteins (Figure 6).

Statistical Analysis

We used SPSS 19.0 for all statistical analyses. Results are shown as the mean±standard deviation. Independent sample *t*-tests were used to analyze the normal distribution between groups.

Discussion

The concept of “therapeutic angiogenesis” was proposed by Isner JM,⁸ that is, “drug-promoted heart self-bypass.” Angiogenesis involves the formation of capillary networks. Ischemia and hypoxia increase vascular permeability, an essential factor in angiogenesis. Under normal physiological conditions, blood vessels in the body maintain high stability once generated but are regulated by many key growth factors with positive or negative regulatory properties. The




Figure 5 DNA methylation, miR200a, and key genes in the different groups. **(A)**: List of candidate solutions for targeted areas of miR200a promoter; **(B)**: heatmap of DNA methylation at different sites (1: MIR200A2-2_CpG_1.2; 2: MIR200A2-2_CpG_4; 3: MIR200A2-2_CpG_7; 4: MIR200A2-2_CpG_8.9; 5: MIR200A2-2_CpG_11; 6: MIR200A2-2_CpG_12.13; 7: MIR200A2-2_CpG_15; 8: MIR200A2-2_CpG_16.17; 9: MIR200A2-2_CpG_19; 10: MIR200A2-2_CpG_22; 11: MIR200A2-2_CpG_24; 12: MIR200A2-2_CpG_27); **(A)** control group; **(B)** model group; **(C)** Panax notoginseng saponin [PNS group]; **(C)**: mean DNA methylation of miR200a promoter using qPCR (n=6); **(D)**: DNA methylation at different miR200a promoter sites (n=6); **(E)**: miR200a level of different groups (n=5); **(F)**: vascular endothelial growth factor (VEGF) level of different groups using ELISA (n=6); **(G)**: ET-1 level of different groups using ELISA (n=6). Compared with the control group, ***P<0.001. Compared with the model group, ###P<0.001.




Figure 6 Hypoxia-induced changes in the phosphorylation of the key genes in the VEGF pathway. Western blot analysis of the key proteins, eNOS (**B**), stat3(**D**), and AKT (**F**), in the VEGF pathway, and their phosphorylation state of eNOS (**A**), stat3(**C**), and AKT(**E**). (**G**), Western blot of key enzymes of the VEGF pathway. Compared with the control group, ** $P < 0.01$ and *** $P < 0.001$, compared with the model group, # $P < 0.05$, ## $P < 0.01$. The sample size is $n = 5$.

initiation of angiogenesis only starts briefly with the emergence of stimulus signals generated by growth factors. Angiogenesis then stops such that the growth and withdrawal of blood vessels maintain a dynamic balance. VEGF is currently the most widely studied growth factor, a powerful mitogenic agent that specifically acts on endothelial cells. It is produced and secreted by many cells and has a strong angiogenic effect.⁹

Interventions in angiogenesis by PNS have been explored in some studies. In 2009, the role of PNS intervention in angiogenesis was reported. Researchers have found that PNS promotes the formation of sub-intestinal vessels in zebrafish. In human umbilical vein endothelial cells (HUVECs), PNS increased the expression of VEGF. Subsequently, several researchers have studied the pro-angiogenic effects of PNS. Notably, some have discovered that PNS can promote endothelial cell angiogenesis, possibly through AMP-activated protein kinase (AMPK)-and eNOS-dependent signaling pathways.¹⁰ Other scholars intervened with PNS in endothelial progenitor cells and found that it

enhanced the expression of proangiogenic factors, such as VEGF and basic fibroblast growth factor.¹¹ In recent years, the cardioprotective effects of PNS, including anti-platelet aggregation, promoting endothelial cell migration, and angiogenesis, have been comprehensively studied in a rat model of anterior descending branch ligation. In a HUVEC model treated with Rg1 and R1, PNS promoted VEGF expression.¹² However, a suitable model is vital for studying the effects of PNS. Through pathological analysis of clinical coronary heart disease, the rat model with anterior descending branch ligation and the HCEAC model with ischemia and hypoxia were the most suitable model choices. We did not examine the expression of angiogenic factors in this study. Instead, we studied the pathological manifestations of PNS intervention in angiogenesis and the molecular expression representing neovascularization. In addition, we explored the mechanism of PNS intervention in angiogenesis from an epigenetic perspective.

Epigenetics is vital in the occurrence and development of CAD. Our previous study showed a DNA methylation-miRNA-mRNA network in CAD, with miR-194 being a key factor.¹³ In an RCT with a double-blind placebo design involving 84 patients with CAD, we observed changes in miR-194 and its methylation after PNS intervention. In subsequent in vitro experiments of PNS intervention, we discovered that PNS significantly altered the levels and methylation of miR-194.⁵ Through sequencing and subsequent validation, we determined the specific expression of miR-200A and its methylation in CAD. This study revealed that angiogenesis-related factors changed significantly after miR200a inhibition, and angiogenesis increased significantly after miR200a inhibition, indicating that miR200a expression is closely related to angiogenesis.

A proangiogenic effect of PNS was observed in rats with MI and HCEACs; however, some limitations remain. First, the observation period could have been longer. Whether an extended study period leads to increased angiogenesis remains unknown. Second, the changes in VEGF and CD31 levels did not match the PCR, ELISA, and Western blotting results. We believe this is related to the different periods of angiogenesis, which changed the expression levels. Future studies should explore this issue. In addition, we discovered that miR200a correlated with angiogenesis. However, it is unknown whether miR200a methylation is relevant to angiogenesis. To date, we have not identified an appropriate method for inhibiting miR200a methylation. Therefore, a novel technique is worth investigating.

Our research shows that PNS can improve angiogenesis in rats with MI and hypoxic HCEACs and affect the degree of miR200a promoter methylation and miR200a and VEGF molecular pathways.

Ethics Statement

The animal studies were reviewed and approved by the institutional ethics committee of Guang Anmen Hospital.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted, and agree to be accountable for all aspects of the work.

Funding

This work was supported by the National Natural Science Foundation of China (No. 81904185, 82230124) and Excellent Young Scientific and Technological Talents of China Academy of Chinese Medicine Sciences (No. ZZ14-YQ-015).

Disclosure

None of the authors declare a conflict of interest. We wish to confirm that there are no known conflicts of interest associated with this publication and that there has been no significant financial support for this work that could have influenced its outcome.

References

1. Rahel B, Suttorp M, Laarman G, et al. Primary stenting of occluded native coronary arteries: final results of the Primary Stenting of Occluded Native Coronary Arteries (PRISON) study. *Am Heart J.* 2004;147:e22. doi:10.1016/j.ahj.2003.11.023

2. Hayward PA, Zhu YY, Nguyen TT, Hare DL, Buxton BF. Should all moderate coronary lesions be grafted during primary coronary bypass surgery? An analysis of progression of native vessel disease during a randomized trial of conduits. *J Thorac Cardiovasc Sur.* 2013;145:140–149. doi:10.1016/j.jtcvs.2012.09.050
3. Duan L, Xiong X, Hu J, Liu Y, Wang J. Efficacy and safety of oral Panax notoginseng saponins for unstable angina patients: a meta-analysis and systematic review. *Phytomedicine.* 2018;47:23–33. doi:10.1016/j.phymed.2018.04.044
4. Duan L, Xiong X, Hu J, Liu Y, Li J, Wang J. Panax notoginseng saponins for treating coronary artery disease: a functional and mechanistic overview. *Front Pharmacol.* 2017;8:702. doi:10.3389/fphar.2017.00702
5. Duan L, Liu Y, Li J, et al. Panax notoginseng saponins alleviate coronary artery disease through hypermethylation of the miR-194-MAPK pathway. *Front Pharmacol.* 2022;13:829416. doi:10.3389/fphar.2022.829416
6. Li N, Rignault-Clerc S, Biemann C, et al. Increasing heart vascularisation after myocardial infarction using brain natriuretic peptide stimulation of endothelial and WT1(+) epicardial cells. *Elife.* 2020;9. doi:10.7554/eLife.61050
7. Isner JM, Rosenfield K, Losordo DW, et al. Percutaneous intravascular US as adjunct to catheter-based interventions: preliminary experience in patients with peripheral vascular disease. *Radiology.* 1990;175:61–70. doi:10.1148/radiology.175.1.2138342
8. Shi Y, Duan X, Xu G, et al. A ribosomal DNA-hosted microRNA regulates zebrafish embryonic angiogenesis. *Angiogenesis.* 2019;22:211–221. doi:10.1007/s10456-019-09663-3
9. Hong SJ, Wan JB, Zhang Y, et al. Angiogenic effect of saponin extract from Panax notoginseng on HUVECs in vitro and zebrafish in vivo. *Phytother Res.* 2009;23:677–686. doi:10.1002/ptr.2705
10. Wang D, Jie Q, Liu B, et al. Saponin extract from Panax notoginseng promotes angiogenesis through AMPK and eNOS-dependent pathways in HUVECs. *Mol Med Rep.* 2017;16:5211–5218. doi:10.3892/mmr.2017.7280
11. Zhu P, Jiang W, He S, et al. Panax notoginseng saponins promote endothelial progenitor cell angiogenesis via the eNOS/β-cadherin pathway. *BMC Compl Med Ther.* 2021;21:53. doi:10.1186/s12906-021-03219-z
12. Wang D, L. L., Y. X., et al. Cardioprotection of Panax notoginseng saponins against acute myocardial infarction and heart failure through inducing autophagy. *Biomed Pharmacother.* 2021;136:111287. doi:10.1016/j.biopha.2021.111287
13. Duan L, Liu Y, Li J, et al. 2022. miR194 hypomethylation regulates coronary artery disease pathogenesis. *BMC Med Genomics.* 15:264. doi:10.1186/s12920-022-01421-7

RETRACTED

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>